Format
Sort by
Items per page

Send to

Choose Destination

Links from PubMed

Items: 1 to 20 of 115

1.

Anti-tumor selectivity of a novel tubulin and HSP90 dual-targeting inhibitor in non-small cell lung cancer models.

Zhang Q, Zhai S, Li L, Li X, Zhou H, Liu A, Su G, Mu Q, Du Y, Yan B.

Biochem Pharmacol. 2013 Aug 1;86(3):351-60. doi: 10.1016/j.bcp.2013.05.019. Epub 2013 Jun 3.

PMID:
23743233
2.

P-glycoprotein-evading anti-tumor activity of a novel tubulin and HSP90 dual inhibitor in a non-small-cell lung cancer model.

Zhang Q, Zhai S, Li L, Li X, Jiang C, Zhang C, Yan B.

J Pharmacol Sci. 2014;126(1):66-76. Epub 2014 Sep 3.

3.

Hsp90 (heat shock protein 90) inhibitor occupancy is a direct determinant of client protein degradation and tumor growth arrest in vivo.

Tillotson B, Slocum K, Coco J, Whitebread N, Thomas B, West KA, MacDougall J, Ge J, Ali JA, Palombella VJ, Normant E, Adams J, Fritz CC.

J Biol Chem. 2010 Dec 17;285(51):39835-43. doi: 10.1074/jbc.M110.141580. Epub 2010 Oct 12.

4.

The anti-proliferative effect of heat shock protein 90 inhibitor, 17-DMAG, on non-small-cell lung cancers being resistant to EGFR tyrosine kinase inhibitor.

Kobayashi N, Toyooka S, Soh J, Yamamoto H, Dote H, Kawasaki K, Otani H, Kubo T, Jida M, Ueno T, Ando M, Ogino A, Kiura K, Miyoshi S.

Lung Cancer. 2012 Feb;75(2):161-6. doi: 10.1016/j.lungcan.2011.04.022. Epub 2011 Jul 20.

PMID:
21767894
5.

The heat shock protein 90 inhibitor, AT13387, displays a long duration of action in vitro and in vivo in non-small cell lung cancer.

Graham B, Curry J, Smyth T, Fazal L, Feltell R, Harada I, Coyle J, Williams B, Reule M, Angove H, Cross DM, Lyons J, Wallis NG, Thompson NT.

Cancer Sci. 2012 Mar;103(3):522-7. doi: 10.1111/j.1349-7006.2011.02191.x. Epub 2012 Feb 9.

6.

Preclinical antitumor activity of the novel heat shock protein 90 inhibitor CH5164840 against human epidermal growth factor receptor 2 (HER2)-overexpressing cancers.

Ono N, Yamazaki T, Nakanishi Y, Fujii T, Sakata K, Tachibana Y, Suda A, Hada K, Miura T, Sato S, Saitoh R, Nakano K, Tsukuda T, Mio T, Ishii N, Kondoh O, Aoki Y.

Cancer Sci. 2012 Feb;103(2):342-9. doi: 10.1111/j.1349-7006.2011.02144.x. Epub 2011 Dec 13.

7.

Synthesis and Evaluation of a Novel Deguelin Derivative, L80, which Disrupts ATP Binding to the C-terminal Domain of Heat Shock Protein 90.

Lee SC, Min HY, Choi H, Kim HS, Kim KC, Park SJ, Seong MA, Seo JH, Park HJ, Suh YG, Kim KW, Hong HS, Kim H, Lee MY, Lee J, Lee HY.

Mol Pharmacol. 2015 Aug;88(2):245-55. doi: 10.1124/mol.114.096883. Epub 2015 May 14.

8.

Novel peptide-dendrimer conjugates as drug carriers for targeting nonsmall cell lung cancer.

Liu J, Liu J, Chu L, Wang Y, Duan Y, Feng L, Yang C, Wang L, Kong D.

Int J Nanomedicine. 2010 Dec 22;6:59-69. doi: 10.2147/IJN.S14601.

9.

Inhibitory effect of riccardin D on growth of human non-small cell lung cancer: in vitro and in vivo studies.

Xue X, Sun DF, Sun CC, Liu HP, Yue B, Zhao CR, Lou HX, Qu XJ.

Lung Cancer. 2012 Jun;76(3):300-8. doi: 10.1016/j.lungcan.2011.12.013. Epub 2012 Jan 17.

PMID:
22261315
10.

Ganetespib (STA-9090), a nongeldanamycin HSP90 inhibitor, has potent antitumor activity in in vitro and in vivo models of non-small cell lung cancer.

Shimamura T, Perera SA, Foley KP, Sang J, Rodig SJ, Inoue T, Chen L, Li D, Carretero J, Li YC, Sinha P, Carey CD, Borgman CL, Jimenez JP, Meyerson M, Ying W, Barsoum J, Wong KK, Shapiro GI.

Clin Cancer Res. 2012 Sep 15;18(18):4973-85. doi: 10.1158/1078-0432.CCR-11-2967. Epub 2012 Jul 17.

11.

A novel histone deacetylase inhibitor exhibits antitumor activity via apoptosis induction, F-actin disruption and gene acetylation in lung cancer.

Tang YA, Wen WL, Chang JW, Wei TT, Tan YH, Salunke S, Chen CT, Chen CS, Wang YC.

PLoS One. 2010 Sep 14;5(9):e12417. doi: 10.1371/journal.pone.0012417.

12.
13.

Efficacy of Hsp90 inhibition for induction of apoptosis and inhibition of growth in cervical carcinoma cells in vitro and in vivo.

Schwock J, Pham NA, Cao MP, Hedley DW.

Cancer Chemother Pharmacol. 2008 Apr;61(4):669-81. Epub 2007 Jun 20.

PMID:
17579866
14.

Blocking heat shock protein-90 inhibits the invasive properties and hepatic growth of human colon cancer cells and improves the efficacy of oxaliplatin in p53-deficient colon cancer tumors in vivo.

Moser C, Lang SA, Kainz S, Gaumann A, Fichtner-Feigl S, Koehl GE, Schlitt HJ, Geissler EK, Stoeltzing O.

Mol Cancer Ther. 2007 Nov;6(11):2868-78.

15.

Sorafenib is efficacious and tolerated in combination with cytotoxic or cytostatic agents in preclinical models of human non-small cell lung carcinoma.

Carter CA, Chen C, Brink C, Vincent P, Maxuitenko YY, Gilbert KS, Waud WR, Zhang X.

Cancer Chemother Pharmacol. 2007 Feb;59(2):183-95. Epub 2006 May 25.

PMID:
16724239
16.

A novel synthetic compound exerts effective anti-tumour activity in vivo via the inhibition of tubulin polymerisation in A549 cells.

Yan J, Pang Y, Sheng J, Wang Y, Chen J, Hu J, Huang L, Li X.

Biochem Pharmacol. 2015 Sep 1;97(1):51-61. doi: 10.1016/j.bcp.2015.07.008. Epub 2015 Jul 23.

PMID:
26212540
17.

NVP-AUY922: a small molecule HSP90 inhibitor with potent antitumor activity in preclinical breast cancer models.

Jensen MR, Schoepfer J, Radimerski T, Massey A, Guy CT, Brueggen J, Quadt C, Buckler A, Cozens R, Drysdale MJ, Garcia-Echeverria C, Chène P.

Breast Cancer Res. 2008;10(2):R33. doi: 10.1186/bcr1996. Epub 2008 Apr 22.

18.

Synergistic activity of the Hsp90 inhibitor ganetespib with taxanes in non-small cell lung cancer models.

Proia DA, Sang J, He S, Smith DL, Sequeira M, Zhang C, Liu Y, Ye S, Zhou D, Blackman RK, Foley KP, Koya K, Wada Y.

Invest New Drugs. 2012 Dec;30(6):2201-9. doi: 10.1007/s10637-011-9790-6. Epub 2012 Jan 10.

19.

Effects of polyphyllin I on growth inhibition of human non-small lung cancer cells and in xenograft.

Kong M, Fan J, Dong A, Cheng H, Xu R.

Acta Biochim Biophys Sin (Shanghai). 2010 Nov;42(11):827-33. doi: 10.1093/abbs/gmq091.

PMID:
20978038
20.

The Hsp90 inhibitor IPI-504 rapidly lowers EML4-ALK levels and induces tumor regression in ALK-driven NSCLC models.

Normant E, Paez G, West KA, Lim AR, Slocum KL, Tunkey C, McDougall J, Wylie AA, Robison K, Caliri K, Palombella VJ, Fritz CC.

Oncogene. 2011 Jun 2;30(22):2581-6. doi: 10.1038/onc.2010.625. Epub 2011 Jan 24.

PMID:
21258415

Supplemental Content

Support Center